泊马度胺

Description

Pomalidomide · CAS 19171-19-8 · C13H11N3O4. UNII D2UX06XLB5.

Identification

CAS Registry Number	19171-19-8
PubChem CID	134780
Molecular formula	C13H11N3O4
IUPAC name	4-amino-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione
UNII (FDA)	D2UX06XLB5

Computed Descriptors

Molecular Weight	273.24
XLogP3	0.2
Hydrogen Bond Donor Count	2
Hydrogen Bond Acceptor Count	5
Rotatable Bond Count	1
Exact Mass	273.07495584
Monoisotopic Mass	273.07495584
Topological Polar Surface Area	110
Heavy Atom Count	20
Formal Charge	0

Physical description & handling notes

• Solid yellow powder
• Limited to low solubility into organic solvents ... low solubility in all pH solutions (about 0.01 mg/mL)
• Stable under recommended storage conditions.
• Pomalidomide is more potent than thalidomide (100-times) and lenalidomide (10-times).
• Table: Pomalidomide Preparations [Table#8206]

GHS Hazard Classification

Reported hazard statements	H361 (10.8%), H373 (81.1%)

Documented Uses

• Angiogenesis Inhibitors; Immunologic Factors
• Pomalidomide is synthesized in two main steps using commercially available well defined starting materials with acceptable specifications. The first step consists of a coupling reaction in which the starting materials react to form crude pomalidomide. The second step is a purification process consisting on filtration, crystallization and drying to obtain the final drug substance.
• Preparation: G. W. Muller et al., World Intellectual Property Organization patent 9803502; eidem, United States of America patent 6335349 (1998, 2002 both to Celgene).
• Pomalidomide is indicated for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and have demonstrated disease progression on or within 60 days of completion of the last therapy. It is also indicated for the treatment of Kaposi's sarcoma (KS) in AIDS patients who have failed highly active antiretroviral therapy (HAART) and for the treatment of KS in HIV-negative patients.
• Pomalidomide is an immunomodulatory and antineoplastic agent that is used in the therapy of multiple myeloma. Pomalidomide, like the structurally related agents thalidomide and lenalidomide, is associated with a low rate of serum aminotransferase elevations during therapy and has been implicated in causing rare instances of clinically apparent liver injury which can be severe.
• Breast Feeding; Lactation; Milk, Human; Immunosuppressive Agents; Angiogenesis Inhibitors

Synonyms

Pomalidomide; 19171-19-8; Actimid; Pomalyst; CC-4047; Imnovid; 4-Aminothalidomide; 4-Amino-2-(2,6-dioxo-3-piperidyl)isoindoline-1,3-dione; 1H-Isoindole-1,3(2H)-dione, 4-amino-2-(2,6-dioxo-3-piperidinyl)-; 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione; IMID-3; 3-Amino-N-(2,6-dioxo-3-piperidyl)phthalimide; IMiD 3; CC 4047; Pomalidomida; D2UX06XLB5

Frequently Asked Questions

What are the CAS number and molecular formula of Pomalidomide?

CAS 19171-19-8; molecular formula C13H11N3O4; molecular weight — g/mol.

What other names is Pomalidomide known by?

Pomalidomide, 19171-19-8, Actimid, Pomalyst, CC-4047, Imnovid.

Is Pomalidomide classified as hazardous?

Hazard statements reported: H361, H373.

Facts on this page are taken from PubChem (US National Library of Medicine) and Wikidata. Grade-specific data — assay, moisture, particle size, packaging, shelf life — is issued per batch on the COA and is not published here.